Physician profile
Michael Mcmahon
NPI 1629072442
$6,119.92
in general payments reported to CMS, 2019-2025
25 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,005 · 2022: $898 · 2023: $1,583 · 2024: $1,903 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029 · Travel and Lodging: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.14 |
| Travel and Lodging | $188.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,848.53 | 2021-2025 | Jot Dx, Cardiomems, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.57 | 2022-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $383.95 | 2023-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $367.63 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $349.64 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $313.85 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $312.25 | 2022-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $301.19 | 2021-2025 | Verquvo |
| Heartflow, INC. | $295.94 | 2022-2025 | Ffrct |
| Novo Nordisk INC | $284.20 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $255.28 | 2021-2024 | Mycarelink, Micra, Cobalt Dr Mri Surescan |
| Pfizer INC. | $243.82 | 2023-2025 | |
| Ge Healthcare | $188.03 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $107.42 | 2024 | Arcalyst |
| Boston Scientific Corporation | $98.88 | 2022-2025 | Watchman Flx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $57.93 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $53.02 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.83 | 2025 | |
| Atricure, INC. | $35.64 | 2024 | |
| Baxter Healthcare | $31.54 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $28.90 | 2023 | Arcalyst |
| Lilly USA, LLC | $23.66 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $23.53 | 2023 | Repatha |
| Amarin Pharma, INC. | $22.76 | 2021 | |
| Bracco Diagnostics INC. | $18.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.